Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : MCNS -- Ignore unavailable to you. Want to Upgrade?

To: Dr. Id who wrote (1067)	12/14/1999 3:38:00 PM
From: R. Bond	Read Replies (1) \| Respond to of 1116

FYI: (BSNS WIRE) Mediconsult Gains New Board Member to Support Continuing Suc Mediconsult Gains New Board Member to Support Continuing Success Business/Technology Editors NEW YORK--(BUSINESS WIRE)--Dec. 13, 1999-- Mediconsult (NASDAQ:MCNS) (www.mediconsult.com) today announced the appointment of Fred F. Nazem to its Board of Directors. "On behalf of the Board of Directors, I would like to welcome Fred Nazem. We are very fortunate to have a person of Fred's standing on our team," said Robert Jennings, CEO of Mediconsult. "His appointment brings additional industry experience as well as investor communications experience. This wealth of knowledge and know-how is important to the ongoing development and rapid growth of Mediconsult, especially given our current leadership position in the marketplace." Nazem has been an entrepreneur, venture capitalist and corporate turnaround executive for more than 25 years. He is the founder and managing partner of Nazem and Company, the Explorer Fund and a co-founder and general partner of the Transatlantic Venture Fund, a joint venture between Nazem and Company and Banque National de Paris of France. He is credited with founding, financing and strategically guiding dozens of trailblazing high-tech healthcare companies including six that have grown from start up to multi-billion dollar enterprises and a number of the fastest growing electronics and medical companies including Cirrus Logic, Genesis Health Ventures and Oxford Health Plans. Michael Treacy, who has served on the Mediconsult board since June 1998, is resigning his position. The board of directors is now comprised of Robert Jennings, Ian Sutcliffe, Barry Guld, John Buchanan and Fred Nazem. About Mediconsult.com, Inc. Mediconsult.com, Inc. through its family of sites is a leading provider of physician and patient healthcare information and services on the World Wide Web. Founded in 1996 with its flagship Web site, www.mediconsult.com, the Company's mission is to improve patient outcomes through information and tools that educate doctors, empower patients and build on the doctor/patient relationship. By educating and empowering consumers to manage their health with in-depth medical information, active support and interactive tools, Mediconsult prepares patients to work effectively with their healthcare provider. By providing physicians with the most current healthcare information and a private community of peers, physicians can offer their patients a higher level of care. This unique, integrated approach has resulted in the largest and most loyal following of medical Web site visitors and a leadership position in the online health industry. The Mediconsult family of sites and communities include: Mediconsult.com (www.mediconsult.com), the medical Web destination patients use most; Mydoctor.com (www.mydoctor.com), visit your doctor online; Physicians' Online (www.pol.net), the world's largest online physician community; Heart Information (www.heartinfo.com), heart health for patients and physicians; PharmInfo (www.pharminfo.com), current and in-depth drug information; Cyberdiet (www.cyberdiet.com), fitness and nutrition resource and community; INCIID (www.inciid.org), infertility information and support; Mediconsultinc.com (www.mediconsultinc.com), redefining medicine through the Internet. Certain statements in this release, such as management's view of future revenues and expenses, may be forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Potential risks and uncertainties include such factors as acceptance of the Company's products and services, competition and other risks described in the Company's filings with the Securities and Exchange Commission.